HomeInvestingOptionsModerna (MRNA) Expects 2024 Launch Of Its RSV Vaccine

Moderna (MRNA) Expects 2024 Launch Of Its RSV Vaccine

Moderna's (MRNA) update to Covid-19 vaccine 2023 sales is a positive, notes Hartaj Singh. He discusses MRNA as he believes that it will lose money this year due to investments in pipeline and product launches. MRNA's earnings were released today, premarket. Its adjusted EPS came in at -$3.62 versus an estimated -$3.84 and revenue came in at $344.00M versus an estimated $290.74M. MRNA sees 2023 Covid-19 vaccine sales of $6B-$8B and expects a 2024 launch of its RSV vaccine. He then compares where MRNA stands in the vaccine marketplace highlighting Pfizer (PFE), Johnson & Johnson, and AstraZeneca (AZN). He analyzes the vaccine marketplace. Tune in to find out more about the stock market today.

Trading 360

03 Aug 2023

SHARE

ON AIR
5:00 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
9:30 am
Market Overtime
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
4:30 pm
Market Overtime
REPLAY
ON AIR
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now